Abstract | BACKGROUND: METHODS: RESULTS: Low objective rates of response and poor survival led to early study termination. Of 17 patients evaluable for response, 6 (35%) demonstrated disease progression during initial TT therapy. Only two objective responses were noted, both in patients with medulloblastoma. Among the 19 patients evaluable for survival, the overall and progression free survivals were 45% and 20%, respectively, at 3 years postdiagnosis. Myelosuppression was the dominant treatment-related toxicity. CONCLUSIONS: Although the numbers of patients were small, thiotepa as used in this study was associated with a poor objective response rate and an unacceptably high rate of disease progression. These results may be partly related to TT's significant myelosuppressive effects and the postponement of more effective chemotherapy.
|
Authors | B I Razzouk, R L Heideman, H S Friedman, J J Jenkins, L E Kun, D L Fairclough, M E Horowitz |
Journal | Cancer
(Cancer)
Vol. 75
Issue 11
Pg. 2762-7
(Jun 01 1995)
ISSN: 0008-543X [Print] United States |
PMID | 7743483
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Vincristine
- Etoposide
- Cyclophosphamide
- Thiotepa
- Cisplatin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Brain Neoplasms
(drug therapy, mortality, radiotherapy, surgery)
- Child, Preschool
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Disease-Free Survival
- Etoposide
(administration & dosage)
- Female
- Humans
- Infant
- Male
- Pilot Projects
- Thiotepa
(therapeutic use)
- Vincristine
(administration & dosage)
|